A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.

Inclusion criteria

• Participant must be 18 to 60 years of age inclusive, at the time of signing the informed consent.
• Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG), vital signs, respiratory rate and body temperature.
• Body weight above or equal 50 kg and body mass index (BMI) within the range 18.0 and 30.0 kg/m^2(inclusive).
• Male and female:

Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

• Male participants: Male participants of reproductive potential must agree to use a condom (with or without spermicide) when sexually active. This applies for the time period between the signing of the informed consent form (ICF) until 5 days after the last dose of study intervention. Female partners of childbearing potential of male participants do not need to follow special precautions.
• Female participants: Women of childbearing potential will have to use highly effective non-hormonal contraception when having sexual intercourse with a male partner from signing the ICF until 5 days after last dose of the study drug. Women of non-childbearing potential are not required to use contraception.

Exclusion criteria

• Any clinically relevant abnormal findings in medical history and physical examination which in the opinion of the investigators, may put the participant at risk because of his/her participation in the trial or provide difficulties in interpreting the trial data.
• Known hypersensitivity to the study interventions (active substances, or excipients of the preparations), or structurally related drugs to CBZ (carbamazepine, e.g. tricyclic antidepressants).
• History of bone marrow depression.
• History of clinically hepatic disorders including hepatic porphyria (e.g. acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).
• History or family history of severe cutaneous reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome.
• Human leukocyte antigen A (HLA-A) *31:01 or human leukocyte antigen B (HLA-B) *15:02 allele.
• History of myotonic dystrophy.
• History of clinically relevant psychiatric disorder, including psychosis or latent psychosis.
• History of epileptic seizures.
• History of clinically relevant depression, or suicidal ideation or behavior.